ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.77%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$616M
AUM Growth
+$616M
(+19%)
Cap. Flow
+$33.1M
Cap. Flow
% of AUM
5.37%
Top 10 Holdings %
Top 10 Hldgs %
49.49%
Holding
239
New
40
Increased
61
Reduced
56
Closed
33
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$52.1M |
| 2 |
Prothena Corp
PRTA
|
$20.5M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 4 |
CytomX Therapeutics
CTMX
|
$6.89M |
| 5 |
ABVX
Abivax
ABVX
|
$6.59M |
Top Sells
| 1 |
RAPT Therapeutics
RAPT
|
$41.5M |
| 2 |
Roivant Sciences
ROIV
|
$17.4M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$8.63M |
| 4 |
Immunovant
IMVT
|
$6.94M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
Sector Composition
| 1 | Healthcare | 83.61% |
| 2 | Financials | 2.95% |
| 3 | Consumer Discretionary | 0% |
| 4 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Pharvaris
PHVS
$1.47B
| $601K | 0.09% |
+34,124
| New | +$601K |
|
102
Lexeo Therapeutics
LXEO
$262M
| $583K | 0.09% |
145,109
-25,339
| -15% | -$102K |
|
103
Kymera Therapeutics
KYMR
$2.87B
| $583K | 0.09% |
13,366
+3,366
| +34% | +$147K |
|
104
OmniAb
OABI
$229M
| $567K | 0.09% |
326,108
+200,000
| +159% | +$348K |
|
105
Merck
MRK
$213B
| $557K | 0.09% |
+7,040
| New | +$557K |
|
106
Pulmonx
LUNG
$71.3M
| $530K | 0.08% |
+204,497
| New | +$530K |
|
|
GRCE
107
Grace Therapeutics, Inc. Common Stock
GRCE
$41.5M
| $525K | 0.08% |
176,627
-166,885
| -49% | -$496K |
|
108
Edgewise Therapeutics
EWTX
$1.57B
| $524K | 0.08% |
40,000
+20,000
| +100% | +$262K |
|
109
Avalo Therapeutics
AVTX
$117M
| $523K | 0.08% |
104,730
+94,730
| +947% | +$473K |
|
110
Spyre Therapeutics
SYRE
$1.01B
| $510K | 0.08% |
34,051
+19,018
| +127% | +$285K |
|
111
WisdomTree Floating Rate Treasury Fund
USFR
$18.8B
| $503K | 0.08% |
10,000
| – | – |
|
112
Denali Therapeutics
DNLI
$2.22B
| $500K | 0.08% |
35,716
+21,843
| +157% | +$306K |
|
113
Sanofi
SNY
$120B
| $483K | 0.07% |
+10,000
| New | +$483K |
|
114
Kiora Pharmaceuticals
KPRX
$9.27M
| $481K | 0.07% |
167,111
-27,554
| -14% | -$79.4K |
|
115
Biohaven
BHVN
$1.69B
| $456K | 0.07% |
32,341
+9,700
| +43% | +$137K |
|
116
Neurogene
NGNE
$277M
| $443K | 0.07% |
29,625
+1,700
| +6% | +$25.4K |
|
117
Nabors Energy Transition Corp II
NETD
$241M
| $443K | 0.07% |
39,900
| – | – |
|
118
Natera
NTRA
$23B
| $422K | 0.06% |
2,500
-1,750
| -41% | -$296K |
|
119
Spero Therapeutics
SPRO
$116M
| $417K | 0.06% |
143,917
-657,360
| -82% | -$1.91M |
|
120
Nektar Therapeutics
NKTR
$557M
| $408K | 0.06% |
15,796
-51,958
| -77% | -$1.34M |
|
121
Eli Lilly
LLY
$657B
| $390K | 0.06% |
500
-100
| -17% | -$78K |
|
122
Protara Therapeutics
TARA
$122M
| $372K | 0.06% |
122,690
| – | – |
|
123
Fulcrum Therapeutics
FULC
$349M
| $367K | 0.06% |
53,349
-437,183
| -89% | -$3.01M |
|
124
PolyPid
PYPD
$54.7M
| $367K | 0.06% |
103,950
+23,870
| +30% | +$84.3K |
|
125
Ventyx Biosciences
VTYX
$174M
| $361K | 0.06% |
168,600
-113,000
| -40% | -$242K |
|